Importantly, blocking EGFR signaling can induce remodeling of the tumor microenvironment (TME) towards an immunoresponsive phenotype in non-small cell lung cancer (NSCLC) and inflammatory breast cancer (70–72). The gene discussed is EGFR; the disease is inflammatory breast carcinoma.